《Table Imaging Follow-up Results》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《A first-in-man study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease(FUTURE-Ⅰ):two-year clinical and imaging outcomes》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

Results Between January and March 2016，a total of 45 patients（age[54.4±9.3]years，22.2%female，and 42.2%unstable angina）with 45 target lesions were enrolled.At 2 years，all patients completed clinical follow up and target lesion failure rate was 0%with no scaffold thrombosis.Imaging follow up was available in 25 patients at 2 years，in-scaffold late lumen loss was 0.42±0.34，and intracoronary imaging confirmed the late lumen loss was mainly attributed to neointimal hyperplasia（neointimal hyperplasia by IVUS:6m F/U=0.18 mm2，1y F/U=0.30 mm2，2y F/U=1.18 mm2，P<0.0001；neointimal area by OCT:6m F/U=1.10 mm2，1y F/U=1.42 mm2，2y F/U=1.88 mm2，P<0.0001），but not scaffold recoil（mean scaffold area by IVUS:6 m F/U=7.9 mm2，1y F/U=8.2 mm2，2y F/U=7.8 mm2，P=0.84；late recoil by OCT:6 m F/U=2.01%，1y F/U=1.94%，2y F/U=1.94%，P=0.98）as shown in Table.